Biodesix (BDSX) Q3 2026 Earnings Call Transcript

Biodesix reported Q3 2026 revenue of $24.0 million, up 10% year over year, with diagnostic testing revenue up 16% and test volume up 24% to approximately 19,400; gross margin was 81%. Results fell short of management expectations amid sales-representative turnover, primary-care seasonality and delayed development-services projects, prompting a reduction in full-year revenue guidance to $101 million–$103 million. Net loss improved 8% to $8.0 million and adjusted EBITDA loss improved 16% to $3.9 million; management reported 110 representatives in the field and plans to reach 115 by year-end.

Analysis

BDSX: growth quality and funding are the key tests. The volume-to-revenue gap points to mix and realization, not just sales execution: if smaller-nodule use sustains a higher Nodify CDT mix, volume can grow while revenue per test stays pressured. Stable gross margin is helpful, but does not solve the need to convert volume into enough gross profit to absorb commercial investment. The sales-force recovery is not yet proof of a durable rebound: October’s new-physician acquisition is a leading indicator, while trained-rep productivity, repeat ordering, and revenue conversion are the evidence that matters.

The CHEST framework and enterprise pathways could lower adoption friction and shift selling from individual clinicians to system-wide workflows. That is a potentially meaningful 6–18 month catalyst, but the framework is not itself a formal guideline change, and implementation timelines leave room for a lag between endorsement and paid test volume. The $8.7 million development-services backlog is similarly not near-term revenue until projects start and samples are processed; management’s conservative 2027 mix outlook argues against treating it as a second growth engine yet.

Liquidity is a material counterweight. Cash fell only modestly despite ATM proceeds, so financing-adjusted cash movement warrants scrutiny; it is not equivalent to operating burn, but continued losses and reliance on equity issuance could dilute shareholders. Near term, the lowered outlook and ramp lag make execution risk asymmetric. Contrarian point: volume growth and system adoption may be underappreciated, but October acquisition alone is insufficient to underwrite acceleration. Reassess after Q4 on test revenue growth, revenue per test, rep productivity, cash use, and actual system-wide reorder rates.

Key Decisions for Investors

• Keep BDSX underweight / avoid adding ahead of Q4 proof; do not initiate a short without checking valuation, borrow availability, and liquidity. The setup is execution-sensitive, and the evidence does not establish a structural demand break.
• Use the next earnings report as the catalyst checkpoint: require diagnostic revenue growth to track volume more closely, stabilization in revenue per test, and improvement in ordering-physician productivity before upgrading the thesis. Falsifier: continued weak revenue conversion despite restored field headcount.
• Track cash and dilution alongside growth. Verify operating cash flow, ATM usage, and runway in the filing; a further material increase in equity issuance or deterioration in cash generation would invalidate the recovery case.
• Treat CHEST-related integrations and BIO/TMO collaborations as strategic optionality, not near-term earnings catalysts. Upgrade only when system implementations produce repeatable ordering data or collaborations demonstrate commercial economics.